AI USE CASE
AI-Assisted Regulatory Submission Drafting
Accelerate regulatory submission preparation for pharma teams using GenAI to auto-draft sections from clinical data.
What it is
This use case applies NLP and generative AI to automatically draft structured sections of regulatory submissions (CTD modules, summaries, narratives) from clinical trial data, study reports, and internal documentation. Teams typically reduce first-draft preparation time by 40–60%, freeing medical writers and regulatory affairs specialists for review and strategy. Submission cycle times can shorten by several weeks per dossier, reducing time-to-market and compliance overhead. The approach also improves consistency across documents, reducing back-and-forth with regulatory bodies.
Data you need
Structured and unstructured clinical trial data, study reports, existing submission templates, and regulatory guidance documents in machine-readable format.
Required systems
- data warehouse
Why it works
- Establish a human-in-the-loop review workflow where qualified medical writers validate every AI-generated section before submission.
- Start with a single, well-documented submission type (e.g., CTD Module 2 summaries) to build confidence before scaling.
- Ensure source clinical data is well-structured, version-controlled, and accessible to the AI pipeline.
- Engage regulatory affairs leadership early to define acceptable AI use policies aligned with agency expectations (EMA, FDA).
How this goes wrong
- AI-generated content contains factual inaccuracies that pass initial review and cause regulatory rejection or delays.
- Clinical source data is stored in incompatible formats or siloed systems, making automated extraction unreliable.
- Regulatory affairs staff distrust AI output and spend more time correcting drafts than writing from scratch.
- Validation and compliance requirements (e.g., 21 CFR Part 11) are not adequately addressed in the deployment, blocking adoption.
When NOT to do this
Do not deploy this solution if your clinical data is fragmented across legacy systems with no data governance, as poor source quality will generate unreliable drafts that erode trust and create regulatory risk.
Vendors to consider
Sources
This use case is part of a larger Data & AI catalog built from 50+ enterprise transformation programs. Take the free diagnostic to see how it ranks against your specific context.